(Reuters) – Alkermes Plc said on Tuesday the U.S. Food and Drug Administration (FDA) approved its drug Lybalvi to treat schizophrenia and bipolar I disorder.
The company expects to commercially launch the drug in the fourth quarter.
(Reporting by Dania Nadeem in Bengaluru; Editing by Aditya Soni)
